Form 4: Relay Therapeutics Director Linda Hill Granted Over 136,000 Stock Options

Relay Therapeutics, Inc. director Linda A. Hill was granted 136,681 stock options with an exercise price of $3.36, vesting over the next year or by the next annual meeting.

Summary

• Linda A. Hill, a Director of Relay Therapeutics, Inc. (RLAY), acquired 136,681 stock options on June 6, 2025.
• The stock options have an exercise price of $3.36 per share.
• These options grant the right to buy 136,681 shares of the Issuer's common stock.
• The options vest in full on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders following the grant date.
• The expiration date for these options is June 5, 2035.
• Following this transaction, Linda A. Hill directly beneficially owns 136,681 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as an insider acquiring options aligns their interests with shareholders and can signal confidence, though it's a routine compensation event.

Positives

• The grant of stock options to a director aligns management's interests with those of shareholders, as the options gain value if the company's stock price increases.
• The acquisition of options by an insider can be viewed as a sign of confidence in the company's future prospects, as the options are only valuable if the stock price rises above the exercise price.

Negatives

• The issuance of new stock options could lead to potential future dilution for existing shareholders if the options are exercised, increasing the total number of outstanding shares.

Risks

• The value of the granted stock options is contingent on the future performance of Relay Therapeutics' common stock; if the stock price does not exceed the exercise price of $3.36, the options may expire worthless.
• Future stock price volatility could impact the realized value of these options for the director.

Future Outlook

The document does not provide a general future outlook for the company, focusing solely on an insider's equity transaction.

Industry Context

This Form 4 filing details a standard equity compensation event for a director within the biotechnology or pharmaceutical industry, where stock options are a common component of executive and board compensation packages designed to incentivize long-term performance and align interests with shareholders.

Comparison to Industry Standards

• The grant of stock options to directors is a common practice across publicly traded companies, particularly in growth-oriented sectors like biotechnology, to attract and retain talent and align their interests with shareholder value creation.
• The vesting schedule, tied to either a one-year anniversary or the next annual meeting, is a typical short-to-medium term vesting period for director equity grants, similar to practices observed in companies like Moderna (MRNA) or BioNTech (BNTX) for their non-employee directors.

Related Party Transactions

• The grant of stock options to Linda A. Hill, a director, constitutes a transaction with a related party, which is a standard component of director compensation.

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also benefit from increased alignment of director's interests with stock performance.
• Employees: No direct impact mentioned in this filing.
• Customers: No direct impact mentioned in this filing.
• Suppliers: No direct impact mentioned in this filing.
• Creditors: No direct impact mentioned in this filing.

Next Steps

• The stock options will vest in full on the earlier of June 6, 2026 (first anniversary of grant date) or the date of Relay Therapeutics' next annual meeting of stockholders following June 6, 2025.
• Linda A. Hill may choose to exercise these options at any time after vesting and before the expiration date of June 5, 2035, assuming the stock price is above the exercise price.

Key Dates

Keywords

Relay Therapeutics, RLAY, Stock Options, Insider Transaction, Form 4, Director Compensation, Equity Grant, Beneficial Ownership, SEC Filing